A VACCINE AGAINST PNEUMONIA

International application PCT/RU2013/000525, priority 22.06.12

Patents for invention

Patent applications for inventions:

• Korea No. 2015-7001672, the filing date 21.01.15,
• Brazil No. 20141132135, the filing date 19.12.14,
• Thailand No. 1401007627, the filing date 19.12.2014,
• Nicaragua No. 2014000153, the filing date 22.12.2014,
• Vietnam’s No. 1-2015-00208, the filing date 21.01.2015.

Pneumococcal infection is often difficult to treat because many circulating epidemic strains ofpneumococcus have acquired multidrug resistance to antibiotics. Vaccines are used to prevent thedevelopment of the disease. According to the position of WHO (World Health Organization) and theRussian respiratory society, “Vaccination is the only way to prevent the development of pneumococcal infection.”

The presentinvention makes it possible to provide universal protection against pneumococci, thanks tothe possibility of both prevention and therapy of diseases caused by Streptococcus pneumoniaepathogen. This is achieved due to the fact that (1) thecentral placeis occupied not by polysaccharides,but by pneumococcal proteins and (2) the vaccine protein is composed of immunogenic epitopes ofseveral conservative pneumococcal proteins, to which a specific immune response is produced with theformation of immunological memory.

The present invention is a vaccine based on a highly purified

fusion protein comprising immunogenic fragments of S. pneumoniae PspA, Spr1895, PsaA proteins, and flagellin components as adjuvant, connected by flexible bridges.

The vaccine is safe due to the active ingredient-recombinant protein, which is obtained using molecular biology and biotechnology.